R
Robert Z. Orlowski
Researcher at University of Texas MD Anderson Cancer Center
Publications - 605
Citations - 40776
Robert Z. Orlowski is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 83, co-authored 543 publications receiving 34699 citations. Previous affiliations of Robert Z. Orlowski include University of Texas Health Science Center at Houston & Duke University.
Papers
More filters
Journal ArticleDOI
Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma
Xiaohui Zhang,Xiaohui Zhang,Hans C. Lee,Fazal Shirazi,Veerabhadran Baladandayuthapani,Heather Lin,Isere Kuiatse,Hua Wang,Richard J. Jones,Zuzana Berkova,Ram Kumar Singh,Jing Lu,Yimin Qian,Kanak Raina,Kevin Coleman,Craig M. Crews,Bingzong Li,H. Wang,Yared Hailemichael,Sheeba K. Thomas,Zhiqiang Wang,R. Eric Davis,Robert Z. Orlowski +22 more
TL;DR: The data demonstrate that BET degraders have promising activity against pre-clinical models of multiple myeloma, and support their translation to the clinic for patients with relapsed and/or refractory disease.
Journal ArticleDOI
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
Qaiser Bashir,Nina Shah,Simrit Parmar,Wei Wei,Gabriela Rondon,Donna M. Weber,Michael Wang,Robert Z. Orlowski,Sheeba K. Thomas,Jatin P. Shah,Sofia Qureshi,Yvonne T Dinh,Uday R. Popat,Paolo Anderlini,Chitra Hosing,Sergio Giralt,Richard E. Champlin,Muzaffar H. Qazilbash +17 more
TL;DR: It is indicated that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion forAuto HCT.
Journal ArticleDOI
The nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma
Bingzong Li,Jinxiang Fu,Ping Chen,Xueping Ge,Yali Li,Isere Kuiatse,Hua Wang,H. Wang,Xingding Zhang,Robert Z. Orlowski +9 more
TL;DR: In this paper, Bortezomib-resistant myeloma models were used to examine the correlation between POMP expression and bortezOMib sensitivity, and showed that the NRF2/POMP axis was associated with increased levels of nuclear factor (erythroid-derived 2)-like (NRF2).
Journal ArticleDOI
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
TL;DR: The hypothesis that proteasome inhibitors activate an anti-apoptotic survival program through p38 MAPK that involves MKP-1 and Akt is supported and it is suggested that strategies targeting MKP to Akt could enhance the anti-tumor efficacy of proteasomesome inhibitors against breast cancer.
Journal ArticleDOI
Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma
TL;DR: This review focuses on the perioperative management of pheochromocytoma and paragangliomas and the clinical implications of the associated genetic mutations.